Published September 6, 2018 | Version v1
Journal article Open

Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures

  • 1. Cancer Data Science Lab, National Cancer Institute, National Institute of Health
  • 2. Department of Biological Regulation, Weizmann Institute of Science
  • 3. University of Maryland Center for Bioinformatics and Computational Biology
  • 4. Department of Plant and Environmental Science, Weizmann Institute of Science
  • 5. Envision Genomics, Huntsville, AL 35806, USA
  • 6. Department of Veterinary Resources, Weizmann Institute of Science
  • 7. Department of Molecular and Human Genetics, Baylor College of Medicine
  • 8. Life Sciences Core Facilities, Weizmann Institute of Science
  • 9. Department of Molecular Cell Biology, Weizmann Institute of Science
  • 10. Faculty of Biology, Technion - Israel Institute of Technology
  • 11. Rady Children's Institute for Genomic Medicine, San Diego
  • 12. Department of Molecular Genetics, Weizmann Institute of Science
  • 13. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston
  • 14. Department of Urology, Basurto University Hospital, Bilbao, Spain; CIBERONC, Madrid, Spain
  • 15. Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore
  • 16. Sackler Faculty of Medicine, Department of Pediatric Hemato Oncology, Sourasky Medical Center, Tel Aviv University
  • 17. CIC bioGUNE, Derio, Spain; CIBERONC, Madrid, Spain
  • 18. Cancer Data Science Lab, National Cancer Institute, National Institutes of Health

Description

The urea cycle (UC) is the main pathway by which mammals dispose waste nitrogen. We find that specific alterations in the expression of most UC enzymes occurs in many tumors, leading to a general metabolic hallmark termed UC dysregulation (UCD). UCD elicits nitrogen diversion towards carbamoyl-phosphate synthetase2, aspartate transcarbamylase and dihydrooratase (CAD) activation and enhances pyrimidine synthesis, resulting in detectable changes in nitrogen metabolites in both patient tumors and bio-fluids. The accompanying excess of pyrimidine vs purine nucleotides results in a genomic signature consisting of transversion mutations at the DNA, RNA and protein levels. This mutational bias is associated with more hydrophobic tumor antigens and with a better response to immune checkpoint inhibitors, independent of mutational load. Taken together, our findings demonstrate that UCD is a common feature of tumors, which profoundly impacts carcinogenesis, mutagenesis and immunotherapy response.

Files

Signature_Cell_ R4_ Final_Merged.pdf

Files (1.1 MB)

Name Size Download all
md5:afb75e29aea8233b152b368d6a0408b7
1.1 MB Preview Download

Additional details

Funding

NO-DISEASE – Developing novel therapies for systemic disorders by regulating Nitric Oxide (NO) substrates' availability 614204
European Commission
INTACt – ImmuNogenomics TArgeting Cancer 754282
European Commission
MetaboMARKER – A metabolism-based prognostic biomarker for prostate cancer 754627
European Commission
CANCERMETAB – Metabolic requirements for prostate cancer cell fitness 336343
European Commission